Targeting DNA Repair in SCLC and the Biomarker Landscape Targeting DNA Repair in SCLC and the Biomarker Landscape
Areas of investigation for SCLC include identification of predictive biomarkers, effective combinations to overcome resistance, and strategies for immunotherapy.Translational Lung Cancer Research (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 16, 2018 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news
New liquid biopsy-based cancer model reveals data on deadly lung cancer
(University of Texas M. D. Anderson Cancer Center) Small cell lung cancer (SCLC) accounts for 14 percent of all lung cancers and is often rapidly resistant to chemotherapy resulting in poor clinical outcomes. Treatment has changed little for decades, but a study at The University of Texas MD Anderson Cancer Center offers a potential explanation for why the disease becomes chemoresistant, and a possible avenue to explore new diagnostic approaches. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 15, 2018 Category: Cancer & Oncology Source Type: news
Current Standards for Clinical Management of SCLC Current Standards for Clinical Management of SCLC
Review the latest on diagnosis, staging, and management of SCLC.Translational Lung Cancer Research (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 15, 2018 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news
PharmaMar's lurbinectedin ATLANTIS trial in SCLC will be an oral presentation
(Pharmamar) PharmaMar's lurbinectedin will have an oral presentation on small-cell lung cancer at the 18th annual meeting on Targeted Therapies in Lung Cancer that is organized by the International Association for the Study of Lung Cancer (IASLC), to be held in Santa Monica Feb. 21-24. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 20, 2018 Category: Cancer & Oncology Source Type: news
Pazopanib Improves PFS in Extensive-Disease SCLC, But Adds Toxicity
Maintenance therapy with pazopanib significantly prolonged progression-free survival in patients with extensive-disease small-cell lung cancer, but with toxicity. (Source: CancerNetwork)
Source: CancerNetwork - February 16, 2018 Category: Cancer & Oncology Authors: Dave Levitan Tags: Lung Cancer News Source Type: news
Clinical Utility of CTCs in Patients With SCLC Clinical Utility of CTCs in Patients With SCLC
Learn how CTCs can be diagnostic, prognostic, and predictive biomarkers in SCLC.Translational Lung Cancer Research (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 10, 2018 Category: Consumer Health News Tags: None Journal Article Source Type: news
Many SCLC Patients Not Receiving Standard of Care Many SCLC Patients Not Receiving Standard of Care
A large proportion of limited-stage small cell lung cancer (SCLC) patients are not receiving standard-of-care treatment. One barrier appears to be coverage with Medicare/Medicaid.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 9, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
One in Five Limited-Stage SCLC Patients Get No Treatment (CME/CE)
(MedPage Today) -- Federally insured patients less likely to get radiation therapy (Source: MedPage Today Radiology)
Source: MedPage Today Radiology - January 5, 2018 Category: Radiology Source Type: news
Small-cell lung cancer patients face barriers to receiving standard-of-care treatment
(University of Texas M. D. Anderson Cancer Center) Despite decades of clinical research establishing chemotherapy with thoracic radiation as the standard-of-care for the initial management of non-metastatic small-cell lung cancer (SCLC), a large percentage of US patients do not receive these treatments and in turn have lower overall survival, according to research from The University of Texas MD Anderson Cancer Center. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - January 4, 2018 Category: International Medicine & Public Health Source Type: news
Biopsy specimen found to be reliable for evaluating DLL3 expression in small cell lung cancer
(International Association for the Study of Lung Cancer) Small cell lung cancer (SCLC) biopsy specimen was found to be reliable material for evaluating DLL3 expression; high levels of DLL3 in SCLC are correlated with poor survival trends. Dr. Li-Xu Yan of Guangdong General Hospital and Guangdong Academy of Medical Sciences in China presented her findings from this study today at the International Association for the Study of Lung Cancer (IASLC) 18th World Conference on Lung Cancer (WCLC) in Yokohama, Japan. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 16, 2017 Category: Cancer & Oncology Source Type: news
New data on PM1183 sees a response rate of 36 percent as single agent in patients with SCLC
(Pharmamar) Up to today, there is only one approved therapy, topotecan, in relapsed disease, that offers a response rate of between 17 percent and 24 percent. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 12, 2017 Category: Cancer & Oncology Source Type: news
Anti-PD 1 Drug Active in Extensive SCLC (CME/CE)
(MedPage Today) -- Pembrolizumab provided 33% response rate in poor-prognosis disease (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - August 24, 2017 Category: Hematology Source Type: news
Study Finds That Proton-Beam Therapy is Safe for Treating an Aggressive Type of Lung Cancer
Proton-beam radiotherapy is safe and appears to be effective in treating some cases of small cell lung cancer (SCLC), an aggressive cancer that accounts for about 10 to 15 percent of all lung cancers, according to a new study published online in the journal Cancer. (Source: University of Maryland School of Medicine News Headlines)
Source: University of Maryland School of Medicine News Headlines - August 10, 2017 Category: Universities & Medical Training Source Type: news
Once-Daily RT Fails to Improve Over Standard in Limited-Stage SCLC
Once-daily RT given concurrently with chemotherapy showed no difference in survival compared with the twice-daily standard in small-cell lung cancer. (Source: CancerNetwork)
Source: CancerNetwork - July 18, 2017 Category: Cancer & Oncology Authors: Dave Levitan Tags: Lung Cancer News Source Type: news
Proton-Beam Therapy in Limited-Stage SCLC Shows Promising Efficacy
Proton-beam therapy was found to be safe for patients with limited-stage small-cell lung cancer in the first prospective registry study of the therapy, with only a small number of high-grade toxicities. (Source: CancerNetwork)
Source: CancerNetwork - July 10, 2017 Category: Cancer & Oncology Authors: Dave Levitan Tags: Lung Cancer News Radiation Oncology Source Type: news
